Imitrex
Product Images NDC 21695-154

Product Visual Gallery

This gallery contains 4 technical images submitted to the FDA as part of the official labeling for Imitrex (NDC 21695-154). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Rebel Distributors Corp, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Imitrex Tablets Chemical Structure (A169b0c0 600f 4072 8ab7 Fafc386eab80 01)

Chemical structure of the active ingredient in IMITREX. The diagram shows molecular bonds and functional groups typical of the compound, presented in a skeletal formula format commonly used in pharmaceutical labeling.*

FDA Label Image

Figure 1. Estimated Probability Of Achieving Initial Headache Response Within 240 Minutes* (A169b0c0 600f 4072 8ab7 Fafc386eab80 02)

A line graph showing the estimated probability of response over time in minutes from the first dose. Four lines represent different treatments: placebo, 25 mg, 50 mg, and 100 mg doses. The probability of response increases with higher doses and time, reaching higher percentages at 240 minutes.*

FDA Label Image

Figure 2. The Estimated Probability Of Patients Taking A Second Dose Or Other Medication For Migraine Over The 24 Hours Following The Initial Dose Of Study Treatment* (A169b0c0 600f 4072 8ab7 Fafc386eab80 03)

A line graph depicting estimated probability of renal isolation for reuse over time in hours after the initial dose. The graph compares placebo and three different doses (25 mg, 50 mg, and 100 mg), showing increasing probabilities over 24 hours with higher doses achieving greater probabilities.*

FDA Label Image

Imitrex 50mg (A169b0c0 600f 4072 8ab7 Fafc386eab80 04)

Packaging label for IMITREX 50 mg tablets by Rebel Distributors Corp, NDC 21695-154-09. The label identifies tablets containing sumatriptan succinate 50 mg, with detailed description of tablet appearance and manufacturer information noting GlaxoSmithKline, Research Triangle Park, NC. Storage instructions and prescription-only status are also shown.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.